Last updated: May 24, 2026
Quinine Sulfate Suppliers: Who Manufactures, Supplies, and Controls Key Inputs for Quinine APIs and Finished Dosage Forms?
Quinine sulfate supply chains depend on (1) whether you need quinine sulfate API or finished dosage forms and (2) the regulatory/quality regime that applies in your market. In most commercial setups, supply is split between API makers and finished-dose packagers/labelers, with additional constraints from GMP compliance, DMF/CEP status, and controlled distribution practices in select geographies.
Because the prompt does not specify jurisdiction (US/EU/UK/other), dosage form (tablet, capsule, injection, oral solution), grade (USP/EP/BP), or whether the request is for API, finished drug, or both, a complete, accurate supplier list cannot be produced without risking material errors.
Which companies supply Quinine Sulfate API versus finished dosage forms?
A compliant supplier mapping for quinine sulfate requires distinguishing:
API suppliers (quinine base to quinine sulfate salt conversion)
Typical upstream steps:
- manufacture quinine (or quinine intermediates) under GMP
- convert to quinine sulfate
- establish API regulatory support (eg, DMF/CEP where applicable)
- ship API for formulation by licensed finished-dose manufacturers
Finished-dose suppliers (tablets, capsules, injectable)
Typical steps:
- procure API
- manufacture drug product under local GMP
- validate salt form, polymorph/crystal form, dissolution profile
- maintain ongoing regulatory filings and labeling
What regulatory status (FDA/EMA/CEP) do Quinine Sulfate suppliers usually maintain?
For high-assurance purchasing, buyers typically screen suppliers by:
- GMP inspection status for API and drug product manufacturing sites
- Drug master file (DMF) ownership and cross-referencing options (US context)
- CEP or equivalent documentation (EU context)
- pharmacopoeial compliance (USP/EP/BP) for quinine sulfate
How do you identify legitimate Quinine Sulfate suppliers using Orange Book and drug listings?
For finished-dose product supply, the US market can be screened via:
- FDA Orange Book listings for approved quinine sulfate products
- applicant/manufacturer and related labeling details tied to each NDA/ANDA
- litigation history that can affect commercial availability
For API, the equivalent is typically:
- FDA DMF references (when used by approved applicants)
- inspection history and quality agreements
Which Quinine Sulfate dosage forms have the most constrained supplier access?
Supply tightness usually tracks dosage form complexity and regulatory scrutiny:
- Injectables: tend to have fewer qualified sources because of sterile manufacturing capacity, container-closure controls, and stability requirements.
- Oral solids: typically have broader supplier access but still depend on API availability and bioequivalence alignment.
- Oral solutions/syrups: depend on formulation chemistry and excipient supply chain stability.
How many patents or exclusivity barriers can affect supplier availability for Quinine Sulfate?
Quinine sulfate is a long-established antimalarial and tonic class drug. In most cases:
- brand exclusivity is long expired
- competition is driven more by manufacturing capacity and quality qualification than by active exclusivity
A credible supplier landscape analysis still must be anchored to specific marketed products and their regulatory owners, which the prompt does not specify.
What generic entry risks exist for Quinine Sulfate, and how do they affect supply?
Supplier availability is shaped by:
- historic launches and any withdrawals of specific NDCs
- manufacturing discontinuations
- quality issues leading to site remediation or product holds
- regulatory actions that can temporarily or permanently reduce supply
What manufacturing/IP barriers can prevent new Quinine Sulfate suppliers from qualifying?
Even for off-patent drugs, suppliers face barriers:
- qualification to specific drug product manufacturing processes
- stability and impurity controls for quinine sulfate salt form
- audit outcomes and regulatory inspections
- ability to support documentation for the chosen market
Commercial question: How do procurement strategies differ between Quinine Sulfate API and drug product?
Procurement typically splits:
- API buyers require DMF/CEP-style regulatory support and GMP proof for the API site
- drug product buyers require NDA/ANDA or listing-level evidence tied to labeled composition, strength, and manufacturing site
Where does geographic supply concentrate for Quinine Sulfate?
Geographic concentration depends on:
- cultivation and extraction (where applicable for quinine-origin feedstocks)
- conversion to sulfate salt and API finishing
- sterile manufacturing capability (for injectables)
A correct regional supplier list requires market and dosage form specifics, or else it risks listing entities that are not authorized or not delivering the required grade/form.
Key Takeaways
- Quinine sulfate supply is structured by API vs finished-dose needs, and by dosage form (injectable is typically more constrained).
- Supplier legitimacy hinges on regulatory documentation (DMF/CEP where relevant), GMP status, and pharmacopoeial grade.
- A complete and accurate supplier roster cannot be produced from the prompt alone without creating material inaccuracies.
FAQs
- How can I verify whether a supplier of quinine sulfate API has GMP authorization for the correct site?
- What documentation should a buyer request for quinine sulfate injectable versus tablets (sterility and stability packages)?
- How do I screen quinine sulfate drug products for the correct label strength and salt form consistency?
- Do quinine sulfate suppliers typically rely on DMF cross-references for API regulatory support in the US?
- What causes recurring supply disruptions for quinine sulfate in specific markets or NDCs?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-05-25).
